Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

914 Dual-antigen targeting via a PMPC-engineered bispecific ADC overcomes tumor heterogeneity and enhances anti-tumor efficacy in advanced ovarian cancer

  • Jie Ren1
  • Masakazu Kamata2
  • Naoki Hama1
  • Srinivasarao Ramisetty3
  • Sreedhari Bulusu1
  • Chloe E Jepson1
  • Arina Thai1
  • Kailey N Lamont1
  • Kevin N Liu1
  • Hunter S Dickens1
  • Yoshiko N Kamata1
  1. 1The University of Alabama at Birmingham, Birmingham, AL, USA
  2. 2Department of Microbiology, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA
  3. 3University of Alabama at Birmingham, Birmingham, AL, USA
Open at sourcePDFDOICite

Related

  1. Fc-Dependent Targeting of the GAS6-MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21.
    Suvendu Giri, Boobash Raj Selvadurai, Nitin Gupta +26
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. CBX3 Deletion Overcomes Ferroptosis Resistance in Colorectal Cancer by Targeting IFNγ/SLC7A11/SLC3A2 Axis
    Y. Xiang, Y. Fu, C. Desterke +13
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  3. 811 AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting
    Su-Hyung Park, Wooick Jang, Jinkeol Mok +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01.
    Xiaojing Wu, Clara Effenberger, Yosuke Matsushita +7
    Journal for immunotherapy of cancerPeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMC
  5. Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer.
    Fang Han, Hongjie Du, Kunlin Tian +4
    Cell death & diseasePeer-reviewedCC BYFull textOncologyEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{ren2026dualantigen,
  title = {{914 Dual-antigen targeting via a PMPC-engineered bispecific ADC overcomes tumor heterogeneity and enhances anti-tumor efficacy in advanced ovarian cancer}},
  author = {Jie Ren and Masakazu Kamata and Naoki Hama and Srinivasarao Ramisetty and Sreedhari Bulusu and Chloe E Jepson and Arina Thai and Kailey N Lamont and Kevin N Liu and Hunter S Dickens and Yoshiko N Kamata},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0914},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0914},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 914 Dual-antigen targeting via a PMPC-engineered bispecific ADC overcomes tumor heterogeneity and enhances anti-tumor efficacy in advanced ovarian cancer
AU  - Jie Ren
AU  - Masakazu Kamata
AU  - Naoki Hama
AU  - Srinivasarao Ramisetty
AU  - Sreedhari Bulusu
AU  - Chloe E Jepson
AU  - Arina Thai
AU  - Kailey N Lamont
AU  - Kevin N Liu
AU  - Hunter S Dickens
AU  - Yoshiko N Kamata
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0914
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0914
SN  - 2051-1426
ER  -